Comparative Effects of 30 Antipsychotics on Risk of Catatonia: An Analysis of the WHO Pharmacovigilance Database

References (31)

1. Dhossche DM, Wachtel LE, Goetz M, et al. Catatonia in psychiatric illnesses. In: Fatemi SH, Clayton PJ, eds. The Medical Basis of Psychiatry. Springer New York; 2016:517–535.
2. Solmi M, Pigato GG, Roiter B, et al. Prevalence of catatonia and its moderators in clinical samples: results from a meta-analysis and meta-regression analysis. Schizophr Bull. 2018;44(5):1133–1150. PubMed CrossRef
3. Sienaert P, Dhossche DM, Gazdag G. Adult catatonia: etiopathogenesis, diagnosis and treatment. Neuropsychiatry (London). 2013;3(4):391–399. CrossRef
4. Fink M, Shorter E, Taylor MA. Catatonia is not schizophrenia: Kraepelin’s error and the need to recognize catatonia as an independent syndrome in medical nomenclature. Schizophr Bull. 2010;36(2):314–320. PubMed CrossRef
5. Rosebush PI, Mazurek MF. Catatonia and its treatment. Schizophr Bull. 2010;36(2):239–242. PubMed CrossRef
6. White DAC. Catatonia and the neuroleptic malignant syndrome: a single entity? Br J Psychiatry. 1992;161(4):558–560. PubMed CrossRef
7. Lee JWY. Neuroleptic-induced catatonia: clinical presentation, response to benzodiazepines, and relationship to neuroleptic malignant syndrome. J Clin Psychopharmacol. 2010;30(1):3–10. PubMed CrossRef
8. Sienaert P, van Harten P, Rhebergen D. The psychopharmacology of catatonia, neuroleptic malignant syndrome, akathisia, tardive dyskinesia, and dystonia. Handb Clin Neurol. 2019;165:41a5–428. PubMed CrossRef
9. Strawn JR, Keck PE Jr, Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry. 2007;164(6):870–876. PubMed CrossRef
10. Tabbane K, Halayem S, Joober R. Clozapine for the management of persistent catatonia. J Psychiatry Neurosci. 2016;41(6):E81–E82. PubMed CrossRef
11. Tsai JH, Yang P, Yen JY, et al. Zotepine-induced catatonia as a precursor in the progression to neuroleptic malignant syndrome. Pharmacotherapy. 2005;25(8):1156–1159. PubMed CrossRef
12. Van Den Eede F, Van Hecke J, Van Dalfsen A, et al. The use of atypical antipsychotics in the treatment of catatonia. Eur Psychiatry. 2005;20(5-6):422–429. PubMed CrossRef
13. Faillie JL. Case-non case studies: principles, methods, bias and interpretation [Les études cas–non cas: principe, méthodes, biais et interpretations]. Therapie. 2018;73(3):247–255. PubMed CrossRef
14. Khouri C, Petit C, Tod M, et al. Adverse drug reaction risks obtained from meta-analyses and pharmacovigilance disproportionality analyses are correlated in most cases. J Clin Epidemiol. 2021;134:14–21. PubMed CrossRef
15. Bergvall T, Norén GN, Lindquist M. VigiGrade: a tool to identify well-documented individual case reports and highlight systematic data quality issues. Drug Saf. 2014;37(1):65–77. PubMed CrossRef
16. Breen J, Hare DJ. The nature and prevalence of catatonic symptoms in young people with autism. J Intellect Disabil Res. 2017;61(6):580–593. PubMed CrossRef
17. Wing L, Shah A. Catatonia in autistic spectrum disorders. Br J Psychiatry. 2000;176(4):357–362. PubMed CrossRef
18. Lao KSJ, Zhao J, Blais JE, et al. Antipsychotics and risk of neuroleptic malignant syndrome: a population-based cohort and case-crossover study. CNS Drugs. 2020;34(11):1165–1175. PubMed CrossRef
19. Schneider M, Regente J, Greiner T, et al. Neuroleptic malignant syndrome: evaluation of drug safety data from the AMSP program during 1993–2015. Eur Arch Psychiatry Clin Neurosci. 2020;270(1):23–33. PubMed CrossRef
20. Nguyen TTH, Pariente A, Montastruc JL, et al. An original pharmacoepidemiological-pharmacodynamic method: application to antipsychotic-induced movement disorders. Br J Clin Pharmacol. 2017;83(3):612–622. PubMed CrossRef
21. Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394(10202):939–951. PubMed CrossRef
22. Reynolds GP. Antipsychotic drug mechanisms and neurotransmitter systems in schizophrenia. Acta Psychiatr Scand suppl. 1994;380(s380):36–40. PubMed CrossRef
23. Hirjak D, Kubera KM, Wolf RC, et al. Going back to Kahlbaum’s psychomotor (and GABAergic) origins: is catatonia more than just a motor and dopaminergic syndrome. Schizophr Bull. 2020;46(2)272–285. PubMed CrossRef
24. Caroff SN, ed. Catatonia: From Psychopathology to Neurobiology. 1st ed. American Psychiatric Pub; 2004.
25. Haroche A, Rogers J, Plaze M, et al. Brain imaging in catatonia: systematic review and directions for future research. Psychol Med. 2020;50(10):1585–1597. PubMed CrossRef
26. Hazell L, Shakir SAW. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006;29(5):385–396. PubMed CrossRef
27. Bégaud B, Martin K, Haramburu F, et al. Rates of spontaneous reporting of adverse drug reactions in France. JAMA. 2002;288(13):1588. PubMed CrossRef
28. Caster O, Aoki Y, Gattepaille LM, et al. Disproportionality analysis for pharmacovigilance signal detection in small databases or subsets: recommendations for limiting false-positive associations. Drug Saf. 2020;43(5):479–487. PubMed CrossRef
29. Pierfitte C, Bégaud B, Lagnaoui R, et al. Is reporting rate a good predictor of risks associated with drugs? Br J Clin Pharmacol. 1999;47(3):329–331. PubMed CrossRef
30. Rogers JP, Pollak TA, Blackman G, et al. Catatonia and the immune system: a review. Lancet Psychiatry. 2019;6(7):620–630. PubMed CrossRef
31. van der Heijden FMMA, Tuinier S, Arts NJM, et al. Catatonia: disappeared or under-diagnosed? Psychopathology. 2005;38(1):3–8. PubMed CrossRef